Taking CAVHANZA
Adherence is simpler with ODT formulation – offering greater flexibility and potentially increasing patient compliance:2
The recommended daily dosage for adult patients is as follows:
| Approved indications | Dosage |
|---|---|
| Newly diagnosed Ph+ CML-CP | 120 mg |
| Resistant or intolerant Ph+ CML-CP | 160 mg |
| Resistant or intolerant Ph+ CML-AP | 160 mg |
Table 1: Daily dosage of CAVHANZA.1
Switching patients from Tasigna® (nilotinib) capsules or Danziten® (nilotinib) tablets:
| Approved indications | CAVHANZA dosage | Tasigna® dosage3 | Danziten® dosage4 |
|---|---|---|---|
| Newly diagnosed Ph+ CML-CP | 120 mg orally twice daily | 300 mg orally twice daily | 142 mg orally twice daily |
| Resistant or intolerant CML-CP and CML-AP | 160 mg orally twice daily | 400 mg orally twice daily | 190 mg orally twice daily |
Table 2: Recommendations for switching patients between CAVHANZA, Tasigna®, or Danziten®.1
| Approved indications | CAVHANZA dosage |
|---|---|
| Newly diagnosed Ph+ CML-CP | 120 mg orally twice daily |
| Resistant or intolerant CML-CP and CML-AP | 160 mg orally twice daily |
| Approved indications | Tasigna® dosage3 |
|---|---|
| Newly diagnosed Ph+ CML-CP | 300 mg orally twice daily |
| Resistant or intolerant CML-CP and CML-AP | 400 mg orally twice daily |
| Approved indications | Danziten® dosage4 |
|---|---|
| Newly diagnosed Ph+ CML-CP | 142 mg orally twice daily |
| Resistant or intolerant CML-CP and CML-AP | 190 mg orally twice daily |
Table 2: Recommendations for switching patients between CAVHANZA, Tasigna®, or Danziten®.1
References
1. CAVHANZA™ (nilotinib) ODT. Prescribing Information. Flex Pharma.
2. Ghourichay, M.P., Kiaie, S.H., Nokhodchi, A. & Javadzadeh, Y. (2021) Formulation and Quality Control of Orally Disintegrating Tablets (ODTs): Recent Advances and Perspectives. BioMed Research International, 2021, Article ID 6618934. Available at: https://doi.org/10.1155/2021/6618934.
3. Tasgina® (nilotinib). Prescribing Information. Novartis Pharmaceuticals.
4. Danziten® (nilotinib). Prescribing Information. Azurity Pharmaceuticals, Inc.
Danziten® is a registered trademark of Azurity Pharmaceuticals, Inc.
Tasigna® is a registered trademark of Novartis AG.
